[go: up one dir, main page]

SMT202400314T1 - Composto di indolo per trattare cistite interstiziale - Google Patents

Composto di indolo per trattare cistite interstiziale

Info

Publication number
SMT202400314T1
SMT202400314T1 SM20240314T SMT202400314T SMT202400314T1 SM T202400314 T1 SMT202400314 T1 SM T202400314T1 SM 20240314 T SM20240314 T SM 20240314T SM T202400314 T SMT202400314 T SM T202400314T SM T202400314 T1 SMT202400314 T1 SM T202400314T1
Authority
SM
San Marino
Prior art keywords
interstitial cystitis
indole compound
treating interstitial
treating
indole
Prior art date
Application number
SM20240314T
Other languages
English (en)
Inventor
Yoshifumi Ueda
Mutsuyoshi Matsushita
Yoshihiro Kitagawa
Akira Matsuo
Tatsuya Maekawa
Sotaro Takigawa
Hiromitsu Watanabe
Naoki Miyagawa
Yuji Hamada
Tetsuya Hondo
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of SMT202400314T1 publication Critical patent/SMT202400314T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM20240314T 2018-05-25 2019-05-24 Composto di indolo per trattare cistite interstiziale SMT202400314T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018100671 2018-05-25
JP2018246392 2018-12-28
US201962835675P 2019-04-18 2019-04-18
EP19733885.8A EP3801546B1 (en) 2018-05-25 2019-05-24 Indole compound for treating interstitial cystitis
PCT/JP2019/021649 WO2019225768A1 (en) 2018-05-25 2019-05-24 Method of treating pain or interstitial cystitis using indole compound

Publications (1)

Publication Number Publication Date
SMT202400314T1 true SMT202400314T1 (it) 2024-09-16

Family

ID=67070891

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240314T SMT202400314T1 (it) 2018-05-25 2019-05-24 Composto di indolo per trattare cistite interstiziale

Country Status (21)

Country Link
US (1) US11464782B2 (it)
EP (2) EP4480484A1 (it)
JP (3) JP6775699B2 (it)
KR (1) KR102725563B1 (it)
CN (1) CN112118843B (it)
AU (1) AU2019274870B2 (it)
BR (1) BR112020022377A2 (it)
CA (1) CA3100675A1 (it)
DK (1) DK3801546T3 (it)
ES (1) ES2983998T3 (it)
FI (1) FI3801546T3 (it)
HR (1) HRP20241045T1 (it)
HU (1) HUE067906T2 (it)
LT (1) LT3801546T (it)
MX (1) MX2020012644A (it)
PL (1) PL3801546T3 (it)
PT (1) PT3801546T (it)
RS (1) RS65837B1 (it)
SI (1) SI3801546T1 (it)
SM (1) SMT202400314T1 (it)
WO (1) WO2019225768A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804727B1 (en) 2018-05-25 2023-10-11 Japan Tobacco Inc. Indol-containing compound for use in the treatment of the nephrotic syndrome
IL293831B2 (en) 2019-12-20 2024-02-01 Pfizer Benzimidazole derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN110845482B (zh) 2014-07-04 2024-01-19 日本烟草产业株式会社 制备吲哚化合物的方法
JP7407705B2 (ja) 2018-05-25 2024-01-04 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
EP3804727B1 (en) 2018-05-25 2023-10-11 Japan Tobacco Inc. Indol-containing compound for use in the treatment of the nephrotic syndrome

Also Published As

Publication number Publication date
HUE067906T2 (hu) 2024-11-28
CA3100675A1 (en) 2019-11-28
CN112118843B (zh) 2023-09-29
EP3801546A1 (en) 2021-04-14
HRP20241045T1 (hr) 2024-11-08
WO2019225768A1 (en) 2019-11-28
BR112020022377A2 (pt) 2021-02-02
RS65837B1 (sr) 2024-09-30
PT3801546T (pt) 2024-08-08
LT3801546T (lt) 2024-08-12
PL3801546T3 (pl) 2024-10-28
CN112118843A (zh) 2020-12-22
US20210205320A1 (en) 2021-07-08
JP6775699B2 (ja) 2020-10-28
FI3801546T3 (fi) 2024-09-05
JP2024096817A (ja) 2024-07-17
SI3801546T1 (sl) 2024-09-30
JP2020525413A (ja) 2020-08-27
AU2019274870A1 (en) 2020-12-17
ES2983998T3 (es) 2024-10-28
AU2019274870B2 (en) 2024-08-08
US11464782B2 (en) 2022-10-11
MX2020012644A (es) 2021-01-29
EP4480484A1 (en) 2024-12-25
JP2021008496A (ja) 2021-01-28
DK3801546T3 (da) 2024-08-12
KR20210014656A (ko) 2021-02-09
KR102725563B1 (ko) 2024-11-05
EP3801546B1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
IL263497B (en) 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment
IL271018A (en) Compounds for the treatment of triple-negative breast cancer
GB201813876D0 (en) Treatment
IL281427A (en) Compounds for the treatment of certain leukemias
GB201800274D0 (en) Novel treatments
IL281052A (en) Treatment of liver disorders
GB2589217B (en) At-the-bit mud loss treatment
GB201709403D0 (en) Compounds for treating sarcoma
ZA201906047B (en) Compounds for treating tuberculosis
SG11202010528XA (en) Combinations for treating cancer
GB201800546D0 (en) Treatment
SG11202102827YA (en) Treatment methods
SG11202102878TA (en) Treatment methods
IL290319A (en) Compound for combined treatment
SI3801546T1 (sl) Indolna spojina za zdravljenje intersticijskega cistitisa
GB201909468D0 (en) Compounds for treating cancer
ZA202103106B (en) Heterocyclic compounds for the treatment of epilepsy
IL278921A (en) Combined treatments for cancer
EP3130586A4 (en) Process for treating homoserine-based compound
GB201909466D0 (en) Compounds for treating cancer
EP3823648C0 (en) METHODS FOR THE TREATMENT OF DIABETES
GB2571849B (en) Treatments for cachexia
GB201814905D0 (en) Treatment
GB201801982D0 (en) Novel treatments
GB201709404D0 (en) Compounds for treating TNBC